Eli Lilly & Co. (LLY)

114.65
1.25 1.10
NYSE : Health Technology
Prev Close 113.40
Open 113.65
Day Low/High 113.22 / 114.83
52 Wk Low/High 84.64 / 132.13
Volume 2.81M
Avg Volume 6.08M
Exchange NYSE
Shares Outstanding 970.83M
Market Cap 108.48B
EPS 3.10
P/E Ratio 42.98
Div & Yield 2.58 (2.16%)
Wake Up Wall Street

Wake Up Wall Street

UAL's earnings are expected today.

Jim Cramer: If There Is a Giant Selloff, I Like Eli Lilly

Jim Cramer: If There Is a Giant Selloff, I Like Eli Lilly

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said that if there is a giant selloff in the broader markets, he likes shares of Eli Lilly LLY.

Takeaways and Observations (Early Edition)

"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Takeaways and Observations

Let me teach you how to Dougie. Consumer confidence is a coincident/lagging indicator. And excitement over the print, is (quite frankly) "first level thinking." As support, check out these two charts of the day -- it's "second level thinking." Snap ...

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

Takeaways & Observations

"I had nothing to offer anybody except my own confusion." -- Jack Kerouac  So, color me confused. But I will persevere and write "Takeaways!"  While a lot didn't make sense, I suspect many traders/investors were caught "offsides."  Peter Boockvar do...

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Eli Lilly: Here's One Drug Company Ready to Rally

Eli Lilly: Here's One Drug Company Ready to Rally

Traders should look to go long on a close above $84.

Cramer: When a Trump Tweet Is a Buy Signal

Cramer: When a Trump Tweet Is a Buy Signal

Drug companies are the latest targets/beneficiaries.

Cowen Health Care Conf.

Cramer: Top 10 Bull Markets Right Now

Cramer: Top 10 Bull Markets Right Now

Bull market number one, perhaps of all time: the financials.

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Cramer: This Drug Rally Is No Longer 'Trumped Up'

Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Snapchat's Parent Prices IPO at Low End of Expectations

Snapchat's Parent Prices IPO at Low End of Expectations

Snap Inc. is preparing for the biggest technology IPO since Alibaba in 2014.

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.

My Takeaways and Observations (Early Edition)

I had my most active day of the year trading. It was also my most profitable.   Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead.   I started the day with a story re...

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

My Takeaways and Observations

I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure.   In other words, I am sticking to my script...

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Eli Lilly upgraded at Morgan Stanley

My Takeaways and Observations

Slow day, at meetings all morning.   Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing.   I reflected on my July call that we have hit a Genera...

Inside Eli Lilly's Surging Stock Price

Inside Eli Lilly's Surging Stock Price

For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.